bs-0208R [Primary Antibody]
GLP-2 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: GLP-2

Immunogen Range: 146-165/180


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 2641

Swiss Prot: P01275

Source: KLH conjugated synthetic peptide derived from human GLP-2

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background:

Glucagon plays a key role in glucose metabolism and homeostasis. Regulates blood glucose by increasing gluconeogenesis and decreasing glycolysis. A counterregulatory hormone of insulin, raises plasma glucose levels in response to insulin-induced hypoglycemia. Plays an important role in initiating and maintaining hyperglycemic conditions in diabetes. GLP-1 is a potent stimulator of glucose-dependent insulin release. Play important roles on gastric motility and the suppression of plasma glucagon levels. May be involved in the suppression of satiety and stimulation of glucose disposal in peripheral tissues, independent of the actions of insulin. Have growth-promoting activities on intestinal epithelium. May also regulate the hypothalamic pituitary axis (HPA) via effects on LH, TSH, CRH, oxytocin, and vasopressin secretion. Increases islet mass through stimulation of islet neogenesis and pancreatic beta cell proliferation. Inhibits beta cell apoptosis. GLP-2 stimulates intestinal growth and up-regulates villus height in the small intestine, concomitant with increased crypt cell proliferation and decreased enterocyte apoptosis. The gastrointestinal tract, from the stomach to the colon is the principal target for GLP-2 action. Plays a key role in nutrient homeostasis, enhancing nutrient assimilation through enhanced gastrointestinal function, as well as increasing nutrient disposal. Stimulates intestinal glucose transport and decreases mucosal permeability. Oxyntomodulin significantly reduces food intake. Inhibits gastric emptying in humans. Suppression of gastric emptying may lead to increased gastric distension, which may contribute to satiety by causing a sensation of fullness. Glicentin may modulate gastric acid secretion and the gastro-pyloro-duodenal activity. May play an important role in intestinal mucosal growth in the early period of life.

Size: 100ul

Concentration: 1ug/ul

Applications: ELISA(1:500-1000)
IHC-P(1:200-400)
IHC-F(1:100-500)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 20


Cross Reactive Species: Human
Rat

Predicted Cross Reactive Species: Mouse
Dog
Cow
Sheep

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Machida M et al. Potentiation of Glucagon-Like Peptide-2 Dynamics by Methotrexate Administration in Rat Small Intestine. Biol Pharm Bull. 2019;42(10):1733-1740.Read more>>
  • Tomomi Akita. et al. Involvement of trigeminal axons in nose-to-brain delivery of glucagon-like peptide-2 derivative. J CONTROL RELEASE. 2022 Nov;351:573Read more>>
VALIDATION IMAGES

Formalin-fixed and paraffin embedded: human stomach tissue labeled with Anti-GLP-2 Polyclonal Antibody, Unconjugated (bs-0208R) at 1:200, followed by conjugation to the secondary antibody and DAB staining


Paraformaldehyde-fixed U2OS cells; Incubated by 0.3% Triton-100 for 20 min; Blocking buffer (normal goat serum) at 37°C for 30min; Antibody incubation with GLP-2 Polyclonal Antibody, Unconjugated (bs-0208R) at 1:200 overnight at 4°C, followed by a conjugated secondary antibody (bs-0295G-FITC) for 90 minutes and DAPI staining.